Oligomerix, a privately-held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, has relocated its corporate headquarters to Valhalla, N.Y. as of Jan. 15, and expanded a lease agreement for additional laboratory space at New York Medical College.

Oligomerix, which is focused on the development of small molecule drugs aimed specifically at inhibiting tau aggregation at the earliest steps of tau self-association into toxic oligomers in neurons, has continued to successfully advance its research, resulting in the need to add staff and expand office and lab space.

Oligomerix recently announced the appointment of James Hendrix, Ph.D., as senior director of chemistry, and plans to potentially recruit up to five employees in 2014.